Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. The expansion broadens access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
According to Cardio Diagnostics, the Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
The collaboration with Atlas Healthcare Physicians signifies a strategic step in expanding the reach of Cardio Diagnostics’ precision medicine offerings. By integrating these tests into managed care populations, the company aims to enhance early detection and personalized management of coronary heart disease, potentially reducing the burden of cardiovascular events. The tests leverage Cardio Diagnostics’ proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, which combines genetic and epigenetic markers to provide individualized risk assessments and diagnostic insights.
Cardio Diagnostics emphasizes that the coverage with prior authorization ensures appropriate use of the tests while making them more accessible to a broader patient population. This approach aligns with the growing trend toward value-based care, where precision diagnostics can help optimize treatment strategies and improve patient outcomes. The company noted that the tests are intended for use in primary care and cardiology settings, facilitating integration into routine clinical practice.
For more details, the full press release is available at https://nnw.fm/EFQen. Information about Cardio Diagnostics and its latest updates can be found in the company’s newsroom at https://ibn.fm/CDIO. Forward-looking statements in this announcement are subject to risks and uncertainties, as detailed in the company's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent quarterly reports.
